F. Durif
15 Papers
43 Citations
F. Durif is an academic researcher. The author has contributed to research in topics: Parkinson's disease & Deep brain stimulation. The author has an hindex of 9, co-authored 15 publications.
Chat about Author
Papers
A Two-Stage Meta-Analysis Identifies Several New Loci for Parkinson's Disease
Vincent Plagnol,Mike A. Nalls,Jose Bras,Dena G. Hernandez,Dena G. Hernandez,M. Sharma,Una-Marie Sheerin,Mohamad Saad,Javier Simón-Sánchez,Claudia Schulte,Suzanne Lesage,Suzanne Lesage,Sigurlaug Sveinbjörnsdóttir,Philippe Amouyel,Philippe Amouyel,S. Arepalli,Roger A. Barker,C. Bellinguez,Yoav Ben-Shlomo,Henk W. Berendse,Daniela Berg,Kailash P. Bhatia,R. M. A. de Bie,Alessandro Biffi,Alessandro Biffi,B.R. Bloem,Zoltán Bochdanovits,Michael Bonin,Knut Brockmann,J. Brooks,David J. Burn,Gavin Charlesworth,Honglei Chen,Patrick F. Chinnery,Sean Chong,Carl E Clarke,Carl E Clarke,Mark R. Cookson,J. M. Cooper,Jean-Christophe Corvol,Carl Counsell,P. Damier,J. F. Dartigues,Panagiotis Deloukas,Günther Deuschl,David T. Dexter,K.D. van Dijk,Allissa Dillman,F. Durif,Alexandra Durr,Sarah Edkins,Jonathan R. Evans,Thomas Foltynie,Colin Freeman,Jianjun Gao,M. Gardner,J. R. Gibbs,J. R. Gibbs,A. Goate,Emma Gray,Rita Guerreiro,O. Gustafsson,Clare Elizabeth Harris,Garrett Hellenthal,J.J. van Hilten,Albert Hofman,Albert R. Hollenbeck,Janice L. Holton,Michele T.M. Hu,X. Huang,Heiko Huber,Gavin Hudson,Sarah E. Hunt,J. Huttenlocher,Thomas Illig,Palmi V. Jonsson,Cordelia Langford,Andrew J. Lees,Peter Lichtner,Patricia Limousin,Grisel Lopez,Delia Lorenz,Alisdair McNeill,C. Moorby,Matthew Moore,Huw R. Morris,Karen E. Morrison,Karen E. Morrison,Ese E. Mudanohwo,Sean S. O'Sullivan,J. P. Pearson,R. Pearson,Joel S. Perlmutter,H. Petursson,Matti Pirinen,Pierre Pollak,Bart Post,Simon C. Potter,Bernard Ravina,Tamas Revesz,O. Riess,Fernando Rivadeneira,Patrizia Rizzu,Mina Ryten,Stephen Sawcer,Peter Heutink,Nicholas W. Wood +106 more
TL;DR: Using a dataset of post-mortem brain samples assayed for gene expression and methylation, methylation and expression changes associated with PD risk variants in PARK16/1q32, GPNMB/7p15, and STX1B/16p11 loci are identified, suggesting potential molecular mechanisms and candidate genes at these risk loci.
Methylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial
Caroline Moreau,Arnaud Delval,Luc Defebvre,Kathy Dujardin,Alain Duhamel,Gregory Petyt,Isabelle Vuillaume,Jean-Christophe Corvol,Christine Brefel-Courbon,Fabienne Ory-Magne,Dominique Guehl,Alexandre Eusebio,Valérie Fraix,Pierre-Jean Saulnier,Ouhaid Lagha-Boukbiza,F. Durif,Mirela Faighel,Caroline Giordana,Sophie Drapier,David Maltête,Christine Tranchant,Jean-Luc Houeto,Bettina Debû,Bernard Sablonnière,Jean-Philippe Azulay,François Tison,Olivier Rascol,Olivier Rascol,Marie Vidailhet,Alain Destée,Bastiaan R. Bloem,Régis Bordet,David Devos +32 more
TL;DR: Methylphenidate improved gait hypokinesia and freezing in patients with advanced Parkinson's disease receiving subthalamic nucleus stimulation and represents a therapeutic option in the treatment of gait disorders at the advanced stage of Parkinson's Disease.
183
Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson's disease.
Caroline Moreau,Sayah Meguig,Jean-Christophe Corvol,Julien Labreuche,Francis Vasseur,Alain Duhamel,Arnaud Delval,Thomas Bardyn,Jean Christophe Devedjian,Nathalie Rouaix,Gregory Petyt,Christine Brefel-Courbon,Fabienne Ory-Magne,Dominique Guehl,Alexandre Eusebio,Valérie Fraix,Pierre Jean Saulnier,Ouhaid Lagha-Boukbiza,F. Durif,Mirela Faighel,Caroline Giordana,Sophie Drapier,David Maltête,Christine Tranchant,Jean-Luc Houeto,Bettina Debû,Jean-Philippe Azulay,François Tison,Alain Destée,Marie Vidailhet,Olivier Rascol,Olivier Rascol,Kathy Dujardin,Luc Defebvre,Régis Bordet,Régis Bordet,Bernard Sablonnière,David Devos +37 more
TL;DR: The preliminary results suggest that variants of SLC6A3 are genetic modifiers of the treatment response to l-DOPA and methylphenidate in Parkinson's disease.
Orodispersible sublingual piribedil to abort OFF episodes: A single dose placebo-controlled, randomized, double-blind, cross-over study†
Olivier Rascol,Jean-Philippe Azulay,Olivier Blin,Anne-Marie Bonnet,Christine Brefel-Courbon,Pierre Cesaro,Philippe Damier,B. Debilly,F. Durif,Monique Galitzky,Jean-Marie Grouin,Sylvie Pennaforte,Gabriel Villafane,Sadek Yaici,Yves Agid +14 more
TL;DR: A single dose of up to 60 mg of S90049 given sublingually was superior to placebo in improving UPDRS III and aborting a practical OFF in patients with advanced PD.
25